Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANYNASDAQ:GREENASDAQ:KFFBNASDAQ:NRBO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANYSphere 3D$0.85-4.2%$0.56$0.36▼$1.90$22.46M3.64570,768 shs500,904 shsGREEGreenidge Generation$1.59-10.7%$0.91$0.58▼$3.84$23.02M3.08505,909 shs703,247 shsKFFBKentucky First Federal Bancorp$2.45-2.4%$2.70$1.96▼$3.62$19.82M0.025,100 shs1,145 shsNRBONeuroBo Pharmaceuticals$0.79-2.5%$1.08$2.08▼$5.30$6.81M-0.2647,183 shs336,069 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANYSphere 3D-4.21%+1.31%+74.69%+27.46%-30.41%GREEGreenidge Generation-10.67%+39.47%+99.00%+47.22%-45.36%KFFBKentucky First Federal Bancorp-2.35%-1.96%-5.95%-20.94%-32.94%NRBONeuroBo Pharmaceuticals+17.29%+19.84%+7.99%-50.62%-81.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANYSphere 3D2.1775 of 5 stars3.53.00.00.03.10.00.6GREEGreenidge Generation3.115 of 5 stars3.52.00.00.02.02.50.0KFFBKentucky First Federal BancorpN/AN/AN/AN/AN/AN/AN/AN/ANRBONeuroBo PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANYSphere 3D 3.00Buy$3.00253.36% UpsideGREEGreenidge Generation 3.00Buy$4.00151.57% UpsideKFFBKentucky First Federal Bancorp 0.00N/AN/AN/ANRBONeuroBo Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NRBO, ANY, KFFB, and GREE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025ANYSphere 3DHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.004/4/2025ANYSphere 3DHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANYSphere 3D$12.48M1.80N/AN/A$1.85 per share0.46GREEGreenidge Generation$59.44M0.39N/AN/A($5.59) per share-0.28KFFBKentucky First Federal Bancorp$8.38M2.37$0.03 per share90.46$5.94 per share0.41NRBONeuroBo PharmaceuticalsN/AN/AN/AN/A$1.50 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANYSphere 3D-$23.41M-$0.57N/AN/AN/A-50.87%-49.54%-34.72%8/12/2025 (Estimated)GREEGreenidge Generation-$29.51MN/A0.00∞N/A-20.09%N/A-18.76%N/AKFFBKentucky First Federal Bancorp-$1.72M-$0.13N/A∞N/A-6.43%-0.49%-0.06%N/ANRBONeuroBo Pharmaceuticals-$12.47MN/A0.00N/AN/AN/A-189.12%-122.31%8/12/2025 (Estimated)Latest NRBO, ANY, KFFB, and GREE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GREEGreenidge GenerationN/A-$0.40N/A-$0.40N/AN/A5/14/2025Q1 2025ANYSphere 3D-$0.26-$0.29-$0.03-$0.32$3.09 million$2.82 million3/28/2025Q4 2024ANYSphere 3D-$0.27-$0.29-$0.02-$0.36$6.72 million$2.64 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANYSphere 3DN/AN/AN/AN/AN/AGREEGreenidge GenerationN/AN/AN/AN/AN/AKFFBKentucky First Federal Bancorp$0.4016.32%N/AN/A N/ANRBONeuroBo PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANYSphere 3DN/A4.094.09GREEGreenidge GenerationN/A1.221.22KFFBKentucky First Federal Bancorp1.291.341.38NRBONeuroBo PharmaceuticalsN/A2.412.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANYSphere 3D17.28%GREEGreenidge Generation8.50%KFFBKentucky First Federal Bancorp3.16%NRBONeuroBo Pharmaceuticals1.37%Insider OwnershipCompanyInsider OwnershipANYSphere 3D5.59%GREEGreenidge Generation27.90%KFFBKentucky First Federal Bancorp3.90%NRBONeuroBo Pharmaceuticals1.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANYSphere 3D2026.46 million24.03 millionOptionableGREEGreenidge Generation68014.48 million8.05 millionNo DataKFFBKentucky First Federal Bancorp608.09 million7.77 millionNot OptionableNRBONeuroBo Pharmaceuticals108.62 million8.53 millionNot OptionableNRBO, ANY, KFFB, and GREE HeadlinesRecent News About These CompaniesMTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…December 4, 2024 | msn.comNeuroBo Pharmaceuticals Rebrands as MetaVia: Strategic Positioning and Growth Potential Highlighted in Buy Rating by Jason McCarthyNovember 21, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals rebrands to become MetaViaNovember 19, 2024 | fiercepharma.comNeuroBo Pharmaceuticals Rebrands Amidst Strategic ChangesNovember 19, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals announces relignment, change nameNovember 19, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic DiseasesNovember 18, 2024 | prnewswire.comNRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024November 13, 2024 | msn.comNeuroBo Pharmaceuticals to Participate in Investor Conferences in NovemberNovember 13, 2024 | prnewswire.comNeuroBo Pharmaceuticals to Present at the November 21st Virtual Investor Summit Microcap EventNovember 12, 2024 | bignewsnetwork.comNeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 7, 2024 | prnewswire.comNeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHNovember 4, 2024 | prnewswire.comNeuroBo Pharmaceuticals (NASDAQ:NRBO) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comNRBO: Positive SAD Part 1 Data; MAD Part 2 Results Expected in 1Q25…October 2, 2024 | msn.comNeuroBo Pharmaceuticals to Participate in Investor Conferences in OctoberOctober 1, 2024 | prnewswire.comNeuroBo Pharma Announces Positive Results From Phase 1 Trial Of DA-1726 In Obesity TreatmentSeptember 30, 2024 | markets.businessinsider.comWe're A Little Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn RateSeptember 30, 2024 | finance.yahoo.comNeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesitySeptember 30, 2024 | prnewswire.comNeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | prnewswire.comNRBO: Data from Part 1 of Phase 1 Trial of DA-1726 in 3Q24…August 21, 2024 | msn.comBuy Rating for NeuroBo Pharmaceuticals Based on Financial Stability and Promising Developmental PipelineAugust 16, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesUnitedHealth Insiders Double Down: Is UNH Stock a Value Play?By Jeffrey Neal Johnson | May 19, 2025View UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?D-Wave Pushes Back on Short Seller Case With Strong EarningsBy Nathan Reiff | May 14, 2025View D-Wave Pushes Back on Short Seller Case With Strong EarningsPalantir’s Latest Deal Could Put a Freeze on Its Stock PriceBy Chris Markoch | May 12, 2025View Palantir’s Latest Deal Could Put a Freeze on Its Stock PriceNVIDIA-Backed CoreWeave Jumps 28%: Is It The Next Great AI Buy?By Leo Miller | May 20, 2025View NVIDIA-Backed CoreWeave Jumps 28%: Is It The Next Great AI Buy?Broadcom's VMware Deal Lifts AVGO Despite Complaints By Leo Miller | April 28, 2025View Broadcom's VMware Deal Lifts AVGO Despite Complaints NRBO, ANY, KFFB, and GREE Company DescriptionsSphere 3D NASDAQ:ANY$0.85 -0.04 (-4.21%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.86 +0.01 (+1.18%) As of 05/23/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sphere 3D Corp. engages in the bitcoin mining business. It is involved with digital asset mining pool operators to provide computing power to the mining pools. The company is based in Stamford, Connecticut.Greenidge Generation NASDAQ:GREE$1.59 -0.19 (-10.67%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.64 +0.05 (+3.46%) As of 05/23/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Greenidge Generation Holdings Inc. operates as an integrated cryptocurrency datacenter and power generation company. The company owns and operates cryptocurrency datacenter in New York, as well as hosts, powers, and provides technical support and other related services to bitcoin mining equipment owned by customers. It also owns and operates a 106 MW nameplate capacity power generation facility. The company was founded in 1937 and is based in Fairfield, Connecticut.Kentucky First Federal Bancorp NASDAQ:KFFB$2.45 -0.06 (-2.39%) As of 05/23/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kentucky First Federal Bancorp operates as the holding company for First Federal Savings and Loan Association of Hazard, and Frankfort First Bancorp, Inc. that provide various banking products and services in Kentucky. It accepts deposit products include passbook savings and certificate accounts, checking accounts, and individual retirement accounts. The company's loan portfolio comprises one-to four-family residential mortgage loans; construction loans; mortgage loans secured by multi-family property; nonresidential loans that are secured by commercial office buildings, churches, and properties used for other purposes; commercial non-mortgage loans; and consumer loans, such as home equity lines of credit, loans secured by savings deposits, automobile loans, and unsecured or personal loans. It also invests in mortgage-backed securities. The company was incorporated in 2005 and is based in Hazard, Kentucky. Kentucky First Federal Bancorp is a subsidiary of First Federal MHC.NeuroBo Pharmaceuticals NASDAQ:NRBO$0.79 -0.02 (-2.48%) As of 05/23/2025NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
